Tilray Brands (TLRY) Cash & Equivalents (2017 - 2026)
Tilray Brands (TLRY) posted Cash & Equivalents of $44.9 million for Q1 2026, down 81.81% on a QoQ basis from $246.7 million in Q4 2025.
Tilray Brands (TLRY) Cash & Equivalents (2017 - 2026) Analysis & Trends
Tilray Brands' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $44.9 million for Q1 2026.
- Quarterly Cash & Equivalents changed N/A year-over-year to $44.9 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $44.9 million (changed N/A YoY) and the FY2024 annual result came in at $228.3 million, up 10.51% from the prior year.
- Cash & Equivalents was $44.9 million for Q1 2026 at Tilray Brands, down from $246.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $490.6 million in Q3 2022 and bottomed at $44.9 million in Q1 2026.
- A 5-year average of $226.3 million and a median of $205.2 million in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 63.82% — and 2024, when it jumped 32.31%.
- Tilray Brands' Cash & Equivalents stood at $190.2 million in 2022, then retreated by 24.63% to $143.4 million in 2023, then soared by 32.31% to $189.7 million in 2024, then soared by 30.05% to $246.7 million in 2025, then tumbled by 81.81% to $44.9 million in 2026.
- Business Quant data shows TLRY's Cash & Equivalents at $44.9 million in Q1 2026, $246.7 million in Q4 2025, and $264.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 44.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 44.89 Mn |
| Nov 30, 2025 | 246.70 Mn |
| Aug 31, 2025 | 264.83 Mn |
| Nov 30, 2024 | 189.70 Mn |
| Aug 31, 2024 | 205.19 Mn |
| May 31, 2024 | 228.34 Mn |
| Feb 29, 2024 | 146.25 Mn |
| Nov 30, 2023 | 143.37 Mn |
| Aug 31, 2023 | 177.52 Mn |
| May 31, 2023 | 206.63 Mn |
| Feb 28, 2023 | 165.00 Mn |
| Nov 30, 2022 | 190.22 Mn |
| Aug 31, 2022 | 490.64 Mn |
| May 31, 2022 | 415.91 Mn |
| Feb 28, 2022 | 279.21 Mn |
| Nov 30, 2021 | 331.78 Mn |
| Aug 31, 2021 | 376.30 Mn |
| May 31, 2021 | 488.47 Mn |
| May 31, 2020 | 360.65 Mn |
| Mar 31, 2020 | 173.99 Mn |